A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2015
At a glance
- Drugs PCO 371 (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 19 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Jun 2015 New trial record
- 25 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.